Overexpression of integrin αv correlates with poor prognosis in colorectal cancer.
OBJECTIVE
Integrin αv subunits are involved in tumour angiogenesis and tumour progression in various types of cancers. Clinical trials evaluating agents targeting integrin αv are ongoing. Integrin αv expression has been reported in several cancers in association with tumour progression or poor survival. However, no study has addressed the prognostic influence of integrin αv expression on survival of patients with colorectal cancer (CRC).


METHODS
Immunohistochemical staining of integrin αv was performed in 198 CRC samples to evaluate its prognostic significance.


RESULTS
High expression of integrin αv was observed in 58.1% (115/189) of colorectal adenocarcinoma samples, while only in 11.5% (3/26) of tubular adenoma samples and in none of normal mucosa or hyperplastic polyp samples. It was more frequently found in female patients and less frequently observed in well differentiated tumours. The proportion of cases with high expression of integrin αv showed an increasing trend with increased T stage (p=0.032), N stage (p=0.006) and TNM stage (p=0.001). Patients displaying exuberant expression of integrin αv showed shorter overall survival (p=0.001) and disease-free survival (p=0.004). Elevated integrin αv expression was an independent prognostic factor for overall survival (HR: 2.04, 95% CI 1.16 to 3.56; p=0.013) and disease-free survival (HR: 2.19, 95% CI 1.16 to 4.13; p=0.015).


CONCLUSIONS
Overexpression of integrin αv is associated with advanced T and N stage and as an independent prognostic factor in CRC.
Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Sang Yun
SY
Ha
Division of Cancer Biology, Comparative Biomedicine Research Branch, Research Institute of National Cancer Center, Goyang, Korea.
Juyoun
J
Shin
Samsung Biomedical Research Institute, Samsung Medical Center, Seoul, Korea Department of Health Sciences and Technology, Sungkyunkwan University School of Medicine, Seoul, Korea.
Jeong Hoon
JH
Kim
Samsung Biomedical Research Institute, Samsung Medical Center, Seoul, Korea Department of Health Sciences and Technology, Sungkyunkwan University School of Medicine, Seoul, Korea.
Myung Soo
MS
Kang
Samsung Biomedical Research Institute, Samsung Medical Center, Seoul, Korea Department of Health Sciences and Technology, Sungkyunkwan University School of Medicine, Seoul, Korea.
Hae-Yong
HY
Yoo
Samsung Biomedical Research Institute, Samsung Medical Center, Seoul, Korea Department of Health Sciences and Technology, Sungkyunkwan University School of Medicine, Seoul, Korea.
Hyeon-Ho
HH
Kim
Department of Cell Biology, Sungkyunkwan University School of Medicine, Suwon, Korea.
Sung-Hee
SH
Um
Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea Samsung Biomedical Research Institute, Samsung Medical Center, Seoul, Korea Department of Health Sciences and Technology, Sungkyunkwan University School of Medicine, Seoul, Korea.
Seok-Hyung
SH
Kim
D000230:Adenocarcinoma / Q000737:chemistry* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D014408:Biomarkers, Tumor / Q000032:analysis*; D002454:Cell Differentiation; D003111:Colonic Polyps / Q000737:chemistry; D015179:Colorectal Neoplasms / Q000737:chemistry* / Q000401:mortality / Q000473:pathology / Q000628:therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D039564:Integrin alphaV / Q000032:analysis*; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D012189:Retrospective Studies; D012307:Risk Factors; D013997:Time Factors; D016896:Treatment Outcome; D015854:Up-Regulation
D014408:Biomarkers, Tumor; D039564:Integrin alphaV
Cancer; Colorectal Cancer; cell-adhesion molecules